For: | Sun HY, Du ST, Li YY, Deng GT, Zeng FR. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 75-89 [PMID: 35116104 DOI: 10.4251/wjgo.v14.i1.75] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v14/i1/75.htm |
Number | Citing Articles |
1 |
Maria Vieito, Matteo Simonelli, Filip de Vos, Victor Moreno, Marjolein Geurts, Elena Lorenzi, Marina Macchini, Martin J van den Bent, Gianluca Del Conte, Maja de Jonge, Maria Cruz Martín-Soberón, Barbara Amoroso, Tania Sanchez-Perez, Marlene Zuraek, Bishoy Hanna, Ida Aronchik, Ellen Filvaroff, Henry Chang, Cristina Mendez, Marina Arias Parro, Xin Wei, Zariana Nikolova, Juan Manuel Sepulveda. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. Neuro-Oncology Advances 2022; 4(1) doi: 10.1093/noajnl/vdac146
|
2 |
Furong Zeng, Yayun Li, Yu Meng, Huiyan Sun, Yi He, Mingzhu Yin, Xiang Chen, Guangtong Deng. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Experimental & Molecular Medicine 2023; 55(2): 364 doi: 10.1038/s12276-023-00936-y
|